PREFerred Neurostimulation MODdalities - PREFMOD Study
Unknown statusNot applicableNCT04582721
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This is a prospective 3x3 crossover study with randomized treatment order, comparing the short-term efficacy of conventional-spinal cord stimulation (CON-SCS) with subcutaneous stimulatio, high frequency-spinal cord stimulation (HF-SCS), and Combination Therapy, in patients with chronic intractable back pain (with or without leg pain).
Study details
- Official title
- PREFerred Neurostimulation MODdalities to Treat Chronic Intractable Back Pain, A 3x3 Crossover Study
- Conditions
- Interventions
- Other: Implantable Neurostimulator System (Spectra WaveWriter™ Spinal Cord Stimulator System), (Boston Scientific Neuromodulation Corporation, Valencia, California (CA), USA)
- Sponsor
- Ospedale Regionale di Lugano
- Collaborators
- Paolo Maino MD PhD, Sponsor Investigator
- Start date
- 2019-04-01
- Primary completion
- 2022-04-09
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Switzerland
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * 18 years or older at inclusion * chronic, intractable back or back and leg pain during at least 6 months * pain intensity of ≥ 5 on a NRS (ranging from 0 to 10) * previous drug therapy unsuccessful Exclusion Criteria: * Psychological disorders * Coagulation disorders * Known immune-deficiency
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04582721